Cost-effectiveness of varenicline for smoking cessation.
Smoking cessation therapies are among the most cost-effective preventive healthcare measures. Varenicline is a relatively new drug developed especially for this purpose, and it has been shown to achieve better quit rates than nicotine replacement therapies and the non-nicotine-based drug, bupropion, which has been in use for some years. The cost-effectiveness of varenicline depends on the cost of the therapy and the cost-savings achieved through reduced morbidity and mortality; several investigations, based on the situation in different countries, indicate that varenicline either finances itself fully through the cost-savings achieved or offers additional life-years at a lower price than that paid elsewhere in the healthcare sector.
Keiding
Hans
H
Department of Economics, University of Copenhagen, Studiestraede 6, DK-1455 Copenhagen K, Denmark. hans.keiding@pop.oko.ku.dk
D001552:Benzazepines / Q000191:economics* / Q000627:therapeutic use; D016642:Bupropion / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D006801:Humans; D009538:Nicotine / Q000191:economics / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000191:economics* / Q000627:therapeutic use; D011810:Quinoxalines / Q000191:economics* / Q000627:therapeutic use; D012907:Smoking / Q000191:economics / Q000401:mortality; D016540:Smoking Cessation / Q000191:economics* / Q000379:methods; D000074606:Smoking Prevention; D000068580:Varenicline
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D009538:Nicotine; D000068580:Varenicline